Trial Profile
A study evaluating safety of Sunitinib and Sorafenib.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Feb 2018
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Sunitinib (Primary) ; Capecitabine
- Indications Cancer
- Focus Adverse reactions
- 13 Feb 2018 New trial record